Chizuko Hashimoto

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology · 2011 · 596 citations

Prognostic impact of extranodal involvement in diffuse large B‐cell lymphoma in the rituximab era

Hiroyuki Takahashi, Naoto Tomita, Masahiro Yokoyama et al. · Cancer · 2011 · 100 citations · Full text

Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type

Yoshinori Ito, Hiroshi Kimura, Yoshinobu Maeda et al. · Clinical Cancer Research · 2012 · 96 citations

Central nervous system event in patients with diffuse large B‐cell lymphoma in the rituximab era

Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto et al. · Cancer Science · 2011 · 88 citations

Neuro-oncology, Lymphoid Neoplasia, Medicine +6

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 88 citations · Full text